BioLineRx (NASDAQ:BLRX) Shares Pass Above 200-Day Moving Average – Here’s Why

Shares of BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $2.87 and traded as high as $3.05. BioLineRx shares last traded at $3.01, with a volume of 221,991 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BioLineRx has a consensus rating of “Sell”.

Get BioLineRx alerts:

Check Out Our Latest Research Report on BioLineRx

BioLineRx Stock Down 4.7%

The company has a market capitalization of $13.15 million, a PE ratio of -1.57 and a beta of 1.55. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average of $3.16 and a 200 day moving average of $2.87.

BioLineRx (NASDAQ:BLRX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.68. The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%.

BioLineRx Company Profile

(Get Free Report)

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.

See Also

• Five stocks we like better than BioLineRx
• A Market Panic Just Discounted the AI Highway’s Tollbooth
• Why Exxon Could Be the Market’s Next Big Comeback Stock
• The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
• Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.